公开(公告)号：US20210324094A1

公开(公告)日：2021-10-21

申请号：US17285367

申请日：2019-10-18

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Ki Joon CHO ,  Mijung LEE ,  Eun Jung SONG ,  Ki Su KIM ,  Kwan Yub KANG ,  Eui Cheol CHO

IPC: C07K16/28 ,  C12N9/16 ,  A61K38/46

Abstract: An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.

公开(公告)号：US20210079062A1

公开(公告)日：2021-03-18

申请号：US16961378

申请日：2019-01-11

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Kwan Yub KANG ,  Taeyoon KIM ,  Jae Hwan RYU ,  Yeon Jung KIM ,  Yong Jae KIM

IPC: C07K14/755 ,  C12N15/63

Abstract: An in-vivo release-sustained recombinant coagulation factor VIII and a method for making it are disclosed. The recombinant coagulation factor VIII has a biocompatible polymer that is conjugated to at least one sugar chain terminus. The in-vivo release-sustained recombinant coagulation factor VIII has a protein surface modified through a method more elaborate and safer than conventional glycoconjugation techniques and enjoys the advantage of decreasing in immunogenicity and increasing in in-vivo sustainability.